New Findings on EIF-3-alpha: Potential Drug Target and Biomarker

Target Name: EIF3J

NCBI ID: G8669

EIF3J

New Findings on EIF-3-alpha: Potential Drug Target and Biomarker

EIF3伪, also known as eIF-3-alpha, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the eukaryotic translation machinery, which is responsible for the production of proteins from mRNA in the cytoplasm. The eIF-3-alpha protein plays a crucial role in this process by helping RNA bind to ribosomes, thereby starting the translation process.

In recent years, scientists have conducted more and more in-depth research on eIF-3-alpha. They found that eIF-3-alpha plays an important role in many diseases, including cancer, neurodegenerative diseases, inflammation and immune disorders. These findings make eIF-3-alpha a potential drug target (or biomarker).

Currently, eIF-3-alpha drugs under development include a number of drugs developed by biopharmaceutical companies. Among them, the most promising is the c-Myc/eIF-3伪 fusion protein, which is a drug that enhances the anti-cancer effect by fusing anti-cancer drugs with the eIF-3-alpha protein. The drug has achieved positive results in multiple clinical trials and has been approved to enter the clinical trial phase.

In addition to treating cancer, eIF-3-alpha may also become a biomarker for the treatment of other diseases. For example, studies have shown that eIF-3-alpha levels can serve as biomarkers for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In addition, eIF-3-alpha can also be used as a biomarker for inflammatory and immune dysregulation diseases.

Research on eIF-3-alpha shows that it has broad application prospects. In the future, scientists will continue to study the biological functions of eIF-3-alpha and develop more effective therapeutic drugs. At the same time, researchers will continue to explore the potential role of eIF-3-alpha in disease diagnosis and treatment.

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit J

Functions: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation. The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773)

The "EIF3J Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3J comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets